#20 – Alongshan Virus: A New Tick-Borne Virus in Europe
A new tick-borne virus has just been detected in Austria for the first time and antibodies found in two people suggest it can infect humans here too. Florian Krammer explains what makes the Alongshan virus so unusual: it belongs to the Jingmen viruses, a group of segmented flaviviruses that are built almost like a hybrid between a flavivirus and an influenza virus. The episode traces how the virus was first discovered in China in 2019, how it has since turned up in ticks across Europe — from Finland to Switzerland, France, Germany and now Austria and what a recent study from the Medical University of Vienna actually found. The takeaway: a fascinating, strange virus with many open questions, but not a cause for concern for now. Scientific article about Alongshan virus in Inner Mongolia: https://www.nejm.org/doi/full/10.1056/NEJMoa1805068 Scientific article about recent Alongshan virus detection in Austria: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00059-5/fulltext +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
- Transcript